Obesity drug maker Novo Nordisk forecast slower growth this year after Wegovy sales more than doubled in the final quarter of ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current best-selling drug in this area, Wegovy ... Novo Nordisk's work goes beyond ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.

A rising number of people have accepted GLP-1s as a way to treat obesity, which affects more than 100 million Americans. © 2024 Fortune Media IP Limited. All Rights ...

Now, a new study finds that Ozempic, along with similar drugs such as Wegovy, has had a broad “economic and societal impact” because of “noticeable shifts in dietary behavior.” The study ...

More and more people are taking weight loss injectables like Wegovy and Mounjaro — and though the drugs are gaining credibility when used properly, pharmacy experts are worried that not everyone ...

Demand for weight loss jabs continues to surge, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. They have also become ...

Commissions do not affect our editors' opinions or evaluations. The value of car insurance can shine brightest after an unexpected disaster. That’s what Kathleen Flynn in Missouri discovered ...